Clinical Trial Update: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight [Phase 3]

View source ↗

Summary

Phase 3 study of retatrutide (LY3437943) in participants with obesity or overweight has completed enrollment and is reporting results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Retatrutide (retatrutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: COMPLETED